All members have the option of attending our various HTC-centric events which include:
|
M
Mon
|
T
Tue
|
W
Wed
|
T
Thu
|
F
Fri
|
S
Sat
|
S
Sun
|
|---|---|---|---|---|---|---|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
1 event,
-
Date: Wednesday, October 4, 2023 Time: 1:00pm - 2:00pm ET TITLE: An injectable, extended half-life recombinant, glycopegylated factor VIII concentrate for Hemophilia A OBJECTIVE: Provide a clinical overview of Esperoct that supports prophylactic, on-demand and perioperative management indications in adults and children. TARGET AUDIENCE: All HTC Staff SPEAKER: Parin Chikani, PharmD, MBA Medical Account Director, Read the full article... |
0 events,
|
0 events,
|
0 events,
|
1 event,
Venue: The St. Anthony Hotel Location: San Antonio, Texas Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568. DRAFT AGENDA: Oct. 8th – Welcome Reception @ 6pm Oct. 9th – Breakfast @ 7:30am; Meeeting: 8:30am – 5:00pm; Group Dinner @ 6:30 pm Oct. 10th - Breakfast @ 7:30am; Meeeting: 8:30am Read the full article... |
|
0 events,
|
1 event,
-
Date: Thursday, October 12, 2023 Time: 1:00pm - 2:00pm ET TITLE: A Label Update on Rebinyn, (Coagulation Factor IX (Recombinant), GlycoPEGylated: FDA Approval for a Prophylaxis Indication for Persons with Hemophilia B OBJECTIVE: Provide a clinical review of Rebinyn that supports prophylaxis, on-demand and perioperative indication in adults and children TARGET AUDIENCE: All HTC Staff Read the full article... |
0 events,
|
0 events,
|
0 events,
|
||
|
0 events,
|
0 events,
|
1 event,
|
0 events,
|
0 events,
|
||
|
0 events,
|
1 event,
-
Date: Tuesday, October 24, 2023 Time: 2:00pm - 3:00pm ET TITLE: A Clinical Overview and Update from Sanofi for Efanesoctocog Alfa, A High Sustained Factor VIII Therapy OBJECTIVES: Highlighting both Efanesoctocog Alfa’s pediatric study, the XTEND-Kids data that were presented at ISTH 2023, as well as an observational study of patients who switched from current Read the full article... |
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
